✦ LIBER ✦

6114 POSTER Clinical Outcomes of Bevacizumab (BV) + XELOX Combination for the First-line Treatment of Patients (pts) With Advanced Cancer of the Colon or Rectum (ACRC) – Preliminary Results of the OBELIX Study

✍ Scribed by Pastorelli, D.; Latiano, T.; Antonuzzo, L.; Pavese, I.; Aieta, M.; Algeri, R.; Azzarello, D.; Bertolini, A.; Di Fabio, F.; Di Costanzo, F.

Book ID: 123160290
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 43 KB
Volume: 47
Category: Article
ISSN: 0959-8049
DOI: 10.1016/S0959-8049(11)71759-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

6594 POSTER First-line bevacizumab in co

6594 POSTER First-line bevacizumab in combination with chemotherapy in the treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): an open-label safety study (MO19390)

✍ Crinó, L.; Dansin, E.; Garrido Lopez, P.; Griesinger, F.; Laskin, J.; Pavlakis, 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 57 KB

476 PFS by patient subgroup for standard

476 PFS by patient subgroup for standard chemotherapies in combination with bevacizumab (BV) in the first-line treatment of HER2-negative locally recurrent (LR) or metastatic breast cancer (mBC): results from RIBBON-1

✍ I. Bondarenko; J. Glaspy; A. Brufsky; O. Lipatov; E.A. Perez; S. Chan; X. Zou; S 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 45 KB